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The diagnostic strategy for chronic thromboembolic pulmonary hypertension (CTEPH)
is composed of two components required for a diagnosis of CTEPH: the presence
of chronic pulmonary embolism and an elevated pulmonary artery pressure. The
current guidelines require that ventilation–perfusion single-photon emission computed
tomography (VQ-SPECT) is used for the first step diagnosis of chronic pulmonary
embolism. However, VQ-SPECT exposes patients to ionizing radiation in a radiation
sensitive population. The prospective, multicenter, comparative phase III diagnostic
Lasch et al. CHANGE-MRI Study Design and Rationale
trial CTEPH diagnosis Europe - MRI (CHANGE-MRI, ClinicalTrials.gov identifier
NCT02791282) aims to demonstrate whether functional lung MRI can serve as an equal
rights alternative to VQ-SPECT in a diagnostic strategy for patients with suspected
CTEPH. Positive findings are verified with catheter pulmonary angiography or computed
tomography pulmonary angiography (gold standard). For comparing the imaging
methods, a co-primary endpoint is used. (i) the proportion of patients with positive MRI
in the group of patients who have a positive SPECT and gold standard diagnosis for
chronic pulmonary embolism and (ii) the proportion of patients with positive MRI in the
group of patients with negative SPECT and gold standard. The CHANGE-MRI trial will
also investigate the performance of functional lung MRI without i.v. contrast agent as an
index test and identify cardiac, hemodynamic, and pulmonary MRI-derived parameters
to estimate pulmonary artery pressures and predict 6–12 month survival. Ultimately,
this study will provide the necessary evidence for the discussion about changes in the
recommendations on the diagnostic approach to CTEPH.
Keywords: MRI, VQ-SPECT, CTEPH, PH, pulmonary embolism, diagnostic strategy
INTRODUCTION
The Clinical Problem
Chronic thromboembolic pulmonary hypertension (CTEPH)
occurs in 0.1–4.0% of patients with acute pulmonary embolism
(PE) within 2 years (1). If left untreated, the outlook for
patients with CTEPH is dismal. Median survival is <2 years
in patients who have a mean pulmonary artery pressure higher
than 30mm Hg at diagnosis (2). Right-heart failure is the most
frequent cause of death. However, when treated successfully
with endarterectomy, CTEPH patients have a good prognostic
outcome (3), therefore timely diagnosis is of great importance.
Advances in management have improved outcomes, but CTEPH
remains a potentially fatal condition, especially when surgery
is not an option (4, 5). The diagnostic approach according
to the current guidelines for CTEPH starts with transthoracic
echocardiography (6) to assess the likelihood of pulmonary
hypertension, followed by ventilation-perfusion single-photon
emission computed tomography (VQ-SPECT) to detect or rule
out perfusion defects (7) (Figure 1). VQ-SPECT is currently the
preferred imaging tool for screening because of its high sensitivity
and a negative predictive value of virtually 100% (9).
The Need for a Trial
VQ-SPECT requires ionizing radiation, while MRI systems are
not associated with any additional radiation dose and have
Abbreviations: BREATH, Biomedical Research in Endstage and Obstructive Lung
Disease Hannover; CPA/CTPA, catheter pulmonary angiography or computed
tomography pulmonary angiography; CTEPH, thromboembolic pulmonary
hypertension; DCE, dynamic contrast-enhanced; MHH, Hannover Medical
School; MRI, magnetic resonance imaging; LGMLC, Universities of Giessen and
Marburg Lung Center; PE, pulmonary embolism; Q-SPECT/CT, perfusion single-
photon emission computed tomography; TLRC-H, Comprehensive Pneumology
Center Munich and the Translational Lung Research Center Heidelberg; USFD,
University of Sheffield; V-SPECT, ventilation single-photon emission computed
tomography; VQ-SPECT, ventilation–perfusion single-photon emission computed
tomography.
increasing availability. Initially, a multicenter study conducted
between 2006 and 2008 in 371 patients with suspected pulmonary
embolism using Gadolinium-enhanced MR Angiography to
detect pulmonary embolism showed amoderate test performance
and modest patient compliance [PIOPED III (10)]. Meanwhile,
novel 4D dynamic contrast-enhanced (DCE) lung perfusion
magnetic resonance imaging (MRI) techniques (11) are widely
available on current MRI systems and have shown excellent test
performance in diagnosing CTEPH in a single center registry
setting in Sheffield [ASPIRE registry (12)]. In addition, a non-
contrast, free breathing ventilation perfusion MRI technique,
known as the Fourier decomposition MRI method (13), has
recently shown initial encouraging results in diagnosing chronic
pulmonary embolism (14). In the CHANGE-MRI study we
implemented phase-resolved functional lung (PREFUL)MRI as a
secondary outcome parameter, which is a further development of
Fourier Decomposition MRI depicting the whole breathing and
cardiac cycle (15). These novel functional MRI techniques hold
significant potential to be an equal rights non-ionizing alternative
to VQ-SPECT in the near future, if they can demonstrate robust
test performance in a prospective multicenter setting (Figure 2).
METHODS AND ANALYSIS
Study Information
CHANGE-MRI is a prospective, multicenter, comparative phase
III diagnostic study undertaken by the German Centre for Lung
Research (DZL): Centre for Biomedical Research in Endstage
and Obstructive Lung Disease Hannover (BREATH), the
Universities of Giessen and Marburg Lung Centre (LGMLC), the
Comprehensive Pneumology Centre Munich, the Translational
Lung Research Centre Heidelberg (TLRC-H), the University
of Sheffield, the Medical University of Vienna, the University
Medical Centre of the Johannes Gutenberg University Mainz,
the University Hospital Zurich and the University Hospital
Regensburg. The study aims to demonstrate that functional lung
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FIGURE 1 | Diagnostic algorithm for CTEPH based on the 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension with potential
change in red (7, 8).
MRI techniques can be an equal rights alternative to VQ-SPECT
as a screening test in a diagnostic strategy for CTEPH where the
positive findings of the screening test are verified with catheter
pulmonary angiography or computed tomography pulmonary
angiography (CPA/CTPA) in the diagnostic work-up.
Investigators from Hannover Medical School (MHH)
designed the trial, and MHH acts as the study sponsor and is
funded by the German Centre of Lung Research (DZL). A trial
management group for the study comprises specialists from
the disciplines of Pneumology, Nuclear Medicine, Radiology,
Biostatistics, Medical Documentation and Medical Imaging
and Computing. The study started recruitment in 2016. Ethical
approval for the study was granted by MHH ethics committee
(No 2678-2015). The trial is registered with ClinicalTrials.gov
identifier NCT02791282.
Objectives
The diagnostic strategy for CTEPH is basically composed of two
components leading to a final diagnosis for or against CTEPH:
1) Presence of chronic pulmonary embolism, and
2) Presence of elevated pulmonary artery pressure.
The tests to be compared in this study (MRI vs. SPECT)
are diagnostic interventions for chronic pulmonary embolism
(chronic PE). Diagnosis of elevated pulmonary artery pressure
follows the routine clinical assessment with right heart
catheterization. As such, the study primarily deals with the first
step diagnosis of chronic pulmonary embolism. The medical
hypothesis of the CHANGE-MRI trial is that the diagnostic
performance of novel functional lung MRI is sufficient to be
an equal rights alternative to VQ-SPECT—the current clinical
standard—in the detection of chronic PE in the diagnostic
algorithm for CTEPH and thus can reduce the radiation burden
for patients. Therefore, theMRI should identify almost all correct
cases in the SPECT—strategy and should not increase the rate of
false positive findings
The study will be considered successful in demonstrating
that MRI can replace SPECT if the following co-primary
hypotheses can be confirmed for the interrelation of MRI
and SPECT:
(i) The probability that MRI is positive in patients who are
SPECT positive and who have a positive gold standard is
larger than 95% and,
(ii) The probability that MRI is positive in patients who are
SPECT negative and who have a negative gold standard is
smaller than 10%.
To determine the sensitivity and specificity of functional MRI
as co-primary endpoints of this diagnostic study, an alternative
strategy would have been to send all study patients for a
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FIGURE 2 | Cardio-pulmonary MRI (A,B,D,E,F,H) and V/Q SPECT (C,G) images of a patient with CTEPH. MRI angiography [coronal maximum intensity projection,
(A)] Maximum intensity projection (MIP) depicts pulmonary artery stenosis and irregularities predominantly in the lower lobes as well as in the left upper lobe. Time
resolved 4D MRI perfusion DCE angiography (coronal, acquisition time per volume: 1.3 s, voxel size 3 × 4 × 5mm, B) depicts corresponding parenchymal
hypoperfusion, which, matches with the Q-SPECT (coronal, voxel size 5 × 5 × 12mm, C) findings. V-SPECT (coronal, voxel size 5 × 5 × 12mm, G) shows relatively
homogeneous ventilation. In accordance, neither infiltrates nor atelectasis are seen on T2 weighted Half-Fourier Acquisition Single-shot Turbo spin Echo (HASTE)-MRI
(coronal, voxel size 2 × 2 × 6mm, F), notice the signal in the main pulmonary arteries due to slow flow. V/Q Phase resolved functional lung MRI (PREFUL, coronal,
voxel size 4 × 4 × 15mm, D,H) depicts normal regional ventilation (H) and regions of hypoperfusion matching the V/Q SPECT (C,G) and DCE MRI (B) findings. Short
axis cardiac cine MRI shows right ventricular hypertrophy and septal flattening (arrow) in systole due to increased pulmonary vascular resistance.
verification step with CPA/CTPA. However, this strategy was
considered to imply an unacceptable increase in the diagnostic
burden and radiation for patients who are not usually subjected
to further diagnostic interventions.
Secondary objectives are:
- To demonstrate an additional benefit of MRI in
comparison to SPECT with correct results of MRI
(according to the gold standard) where SPECT showed
false diagnoses
- To compare the performance of SPECT and MRI using
conventional diagnostic measures: sensitivity, specificity,
positive and negative predictive value
- to compare the performance of SPECT and MRI in subgroups
of male and female and obese (BMI ≥ 28 kg/m2) and non-
obese (BMI < 28 kg/m2) patients
- to evaluate the inter-rater reliability in SPECT assessment,
MRI-assessment and CPA/CTPA assessment between local in-
place read and blinded read
- to compare SPECT and MRI regarding safety and procedure
related limitations.
Patients
The inclusion criteria are chosen to reflect exactly the
clinical setting in the diagnostic algorithm for CTEPH. Here,
MRI is positioned for an in-place validation compared to
SPECT without any exclusion of subgroups compared to
TABLE 1 | Patient inclusion and exclusion criteria.
Inclusion • Transthoracic echocardiography suggests
pulmonary hypertension
• Patients with clinical suspicion for CTEPH, scheduled
for SPECT
• Provided informed consent for the study
• Age >18 years
Exclusion • Inability to undergo MRI (e.g., due to claustrophobia, cardiac
pacemaker, hypersensitivity to MR i.v. contrast
imaging agents)
• Women who are pregnant or breast feeding
SPECT, except for inability to undergo MRI and pregnancy
(see Table 1).
Diagnostic Methods
Index Test
A robust functional cardio-pulmonary-MRI exam that can be
conducted within 30min without radiation burden is used as
novel index test. In brief, theMRI protocol consists of anatomical
MR sequences, to depict thoracic pathology (ECG gated steady
state free precession sequences and Half-Fourier Acquisition
Single-shot Turbo spin Echo imaging covering the whole thorax
both in axial and coronal planes), coronal 2D Fast low Angle Shot
stacked time series for 50 sec each covering the whole thorax
and 2 additional sagittal 2D Fast low Angle Shot planes (one for
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each lung) in free breathing for PREFULMRI, contrast enhanced
pulmonary MRA (4D time resolved gradient echo MRA and 3D
pulmonary MRA, total gadolinium dose 1.5 mmol/kg) as well
as cardiac function (short axis cine stack and 4 chamber cine
view). While retrospectively ECG gated cardiac cine sequences
are used in the study protocol, novel fast real-time cardiac cine
sequences (i.e., compressed sensing MRI techniques) may be
used, especially in cases of arrhythmia or shortness of breath
(16). For detailed description of the MRI protocol see Figure 3. A
central read for cardiac function and strain analysis is performed
using dedicated cardiac software (CMR42, Circle Cardiovascular
Imaging). For the primary read all MRI data is available except
PREFUL MRI. In a sub-study all MRI data is available except 4D
time resolved gradient echo MRA and 3D pulmonary MRA to
test PREFUL as a secondary outcome parameter without the need
for i.v. contrast for CTEPH diagnosis.
FIGURE 3 | Detailed description of the MRI protocol.
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Reference Test
VQ-SPECT is used as the reference test in this study. In
clinical practice, several CTEPH expert centers use perfusion
single-photon emission computed tomography (Q-SPECT/CT)
without concomitant ventilation SPECT (V-SPECT) to exclude
or diagnose CTEPH, although not in compliance with the
current ERS/ESC guidelines (8, 17). Therefore, in this study also
Q-SPECT/CT is accepted as reference test, reflecting current
clinical practice and real-world test performance. In this article,
the reference test of VQ-SPECT or Q-SPECT/CT is termed
SPECT. The duration of the intervention is ∼60min per patient.
The radiation exposure applied by the reference test is ∼1.2–2
mSv (17).
Diagnostic Gold Standard
Catheter pulmonary angiography or computed tomography
pulmonary angiography (CPA/CTPA) is considered to be the
current clinical gold standard for confirming chronic pulmonary
embolism in a diagnostic algorithm (7). CTPA and CPA are well
suited as verification step for the diagnosis of chronic pulmonary
embolism (18). Nevertheless, they both have a considerable
radiation burden on the patient. Therefore, in current diagnostic
practice, in many expert centers only patients with a positive
SPECT undergo a verification step with CPA/CTPA, whereas
at some sites CPA/CTPA is used for verification of all patients.
In this study, we only verify patients, if verification with
CPA/CTPA is clinical routine at the respective study site. It is
the responsibility of the treating pneumologist to decide whether
verification by CPA/CTPA is clinically indicated. In any case,
verification with CPA/CTPA is not part of study directives but
a clinical decision.
A clinical follow-up after 6–12 months is implemented, where
all patients are contacted and asked whether there has been any
further intervention indicative (or contraindicative) of CTEPH,
in order to identify cases diagnosed as false negative (or false
positive, respectively) in the diagnostic work-up. Additionally,
cases diagnosed as false negative by the screening test (SPECT
negative patients are not verified by CPA/CTPA on a regular
basis), but subsequently identified as positive can be captured by
incorporation of the clinical follow up. Since the gold standard
should capture the true diagnosis at inclusion, the clinical follow
up diagnosis is restricted to be within 1 year of the inclusion to
ensure that CTEPH—if diagnosed in the clinical follow up—was
present at the inclusion already and did not develop afterwards.
With this trial design we avoid an increase in the diagnostic
burden (i.e., the increased radiation of CPA/CTPA) for SPECT-
negative patients without clinically indicated CPA/CTPA. A
verification of all patients (to precisely estimate the sensitivity
and specificity of functional MRI) was considered infeasible and
ethically indefensible due to the application of the additional
radiation dose required for CPA/CTPA without any clinical
justification. Consequently, a composite gold standard for
pulmonary embolism used in this trial combining SPECT,
CPA/CTPA and follow-up. The composite gold standard is a
diagnostic strategy with SPECT as screening test and CPA/CTPA
as verification test, corrected by clinical diagnosis after 6–
12 months:
• If CPA/CTPA is performed during the initial diagnostic work-
up, the gold standard is set to the result of CPA/CTPA
corrected for the clinical diagnosis after 6–12 months. In cases
of mismatch, the clinical 6–12 months follow-up diagnosis
overrules the CPA/CTPA diagnosis (e.g., if CPA/CTPA
diagnosis is negative but 6–12months diagnosis is positive, the
gold standard diagnosis is positive).
• If CPA/CTPA has not been conducted during initial diagnostic
work-up, the gold standard is set to the clinical diagnosis after
6–12 months.
Clinical Routine and Study Flow
Figure 4 illustrates the current diagnostic work-up for
pulmonary embolism in the diagnostic strategy for CTEPH,
the additionally conducted study procedures and the path of
verification and diagnostic decision in the CHANGE-MRI trial.
In-place Assessment
In this study at each site standard operating procedures are
implemented with the aim that the in-place assessment of SPECT
(following the clinical routine) and MRI are performed and
evaluated independently by two different readers from different
teams. The respective diagnoses are termed in-place assessments
and are used for secondary analyses. Both readers are aware of
the medical history of the patient under investigation but are not
allowed to know the diagnosis made with the aid of the other test,
as the reference test is already clinically established and, as such,
bares some information. In accordance, the system for electronic
Case Report Forms is set up in a way that each reader‘s access is
restricted to the respective imaging method.
If required by the treating pneumologist, CPA/CTPA is
performed and evaluated at the study site, as well.
Blinded-Reader Assessment
A centrally organized blinded reader assessment of SPECT
and functional MRI will be implemented to ensure that no
information carry-over occurs from clinical SPECT diagnosis
to the functional MRI diagnosis or vice versa. Therefore, this
blinded reader assessments will be used for the primary analysis.
All SPECTs and functional MRIs will undergo a blinded read
where independent expert readers are randomly selected for
each center and each imaging method from one of the other
centers. The second reader is not aware of the findings from
the initial in-place read and the respective other imaging
method but has access to the patient‘s clinical information used
in the in-place SPECT read. Additional to ensuring a truly
blinded assessment of the imaging methods, the standardized
blinded reader assessment allows assessing inter-rater agreement
and context sensitivity of the diagnostic evaluations. If there
is a discrepancy between the in-place read and the second
reader, a final consensus read will be performed by a third
expert reader.
Outcome Measures
SPECT and MRI will be compared based on a standardized
blinded reader assessment of the imaging methods as well
as based on the in-place assessments as part of a workflow
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FIGURE 4 | Integration of the MRI scan in the clinical workflow in the CHANGE-MRI study.
incorporated into the clinical routine. To definitely exclude
information carry-over in the primary analysis, the following
co-primary endpoints are calculated based on the standardized
blinded reader assessment:
- The proportion of patients with positive MRI in the group
of patients who have a positive SPECT diagnosis for chronic
pulmonary embolism andwho are positive in the gold standard
- The proportion of patients with positive MRI in the group
of patients with negative SPECT who are negative in
the gold standard.
The co-primary endpoint will also be analyzed based on
the in-place assessment and results will be compared to
assess the inter-rater agreement and context sensitivity of the
diagnostic evaluations and to evaluate the external validity and
generalizability of the primary results. Additional secondary
endpoints based on the in-place assessment and the blinded-
reader assessment include the diagnostic measures sensitivity,
specificity, positive and negative predictive values of MRI and
SPECT as compared to the defined gold standard. To assess
additional benefit of the MRI compared to the SPECT, the
proportion of patients with positive MRI in the group of patients
who have a negative SPECT, but are positive in the gold standard,
and the proportion of patients with negative MRI in patients
who are SPECT positive, but have a negative gold standard, will
be evaluated.
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To assess the safety, the occurrence of allergic reactions or
other adverse events, non-completed procedures, reasons for
non-completion, non-diagnostic procedures, reasons for non-
diagnostic, and the quality of the images will be evaluated for both
imaging techniques.
Sample Size
The sample-size calculation was based on a substudy from
the Sheffield ASPIRE registry with 132 patients suspected for
CTEPH (12). The prevalence of CTEPH was around 60% here,
sensitivities and specificities were 96 and 90% for Q-SPECT
and 97 and 92% for functional MRI. It was not appropriate
to directly utilize these numbers for sample size estimation:
First, the primary analysis of the CHANGE-MRI trial uses
different, unconventional endpoints due to the incomplete
verification by CPA/CTPA. Second, it was unclear, in how far
unverified (by CPA/CTPA) patients will occur in the study
setting and how large the resulting differential verification
bias might be.
Thus, a simulation study was conducted based on the
ASPIRE study simulating 1,000 patients in different scenarios.
Estimates for the primary endpoint proportions were taken
from the mean diagnostic table of 5,000 simulation runs (see
Table 2): the proportions of patients with positive MRI within
those with positive SPECT and positive gold standard was
estimated to be 98% and the proportion of patients with
positive MRI within those with negative SPECT and negative
gold standard was estimated to be 6%. These estimates were
used for sample size calculations with a Chi2-test. For both
co-primary hypotheses, a one-sided type-I-error of 2.5% and
a power of 80% were used. Sample size calculations for the
individual hypothesis resulted in 331 patients with positively
verified SPECT and 388 patients with negative SPECT and
negative gold standard. To calculate the expected overall sample
size to achieve this sample sizes for the subgroups, the expected
diagnostic table was calculated based on the simulation study.
For each hypothesis, the expected overall sample size was
calculated taking into account the expected prevalence of each
subgroup (58 and 36%, respectively, see Table 2). Consequently,
the final sample size was determined by the higher sample
size, which is associated with the second primary objective
[Table 2, part (b)]. A total of N = 1080 required patients
are anticipated.
Statistical Analysis
The primary analysis will be performed in a modified intention-
to-treat population, i.e., patients will only be excluded from the
analysis, if for all three diagnostic tests no assessment (neither
in-place nor blinded) is available and no further follow-up
data on the clinical diagnosis after 6–12 months is available.
The overall two-sided type-I-error probability is set to 5%.
Point estimates and 95% Wilson confidence intervals will be
calculated for both co-primary endpoints based on the blinded
reader assessments. Since both endpoints are evaluated co-
primarily, no correction for the overall type-I-error probability
is necessary.
Imputation of missing values is conducted dependent on
whether any assessments of SPECT, MRI or CPA/CTPA images
and clinical follow up diagnosis are available or not. If either in-
place or blinded reader assessments are available, missing values
of MRI or SPECT will preferably be replaced by the results of
the respective available assessments. In the case of missing values
because the test has not been performed at all or neither in-
place nor blinded assessment are available, missing values of
TABLE 2 | Sample size calculation based on a simulation study: (A) Expected diagnostic table and (B) expected required sample sizes for the co-primary endpoints.
(A) Expected diagnostic table
Gold standard
+ –
SPECT SPECT
+ – + –
MRI + 562 (98%)* 20 (82%)* 11 (28%)* 21 (6%)*
– 14 (2%)* 4 (18%)* 29 (72%)* 339 (94%)*
Sum 576 (58%)# 24 (2%)# 40 (4%)# 360 (36%)# 1000
(B) Expected required sample sizes for co-primary endpoints
(1) Proportion of patients with MRI+ if gold standard+ and SPECT+
Expected:
98%
Targeted:
Min 95%
Required patients gold
standard+ and SPECT+:
331
Expected total number
required:
571
(2) Proportion of patients with MRI+ if gold standard– and SPECT–
Expected:
6%
Targeted:
Max 10%
Required patients gold
standard– and SPECT–:
388
Expected total number
required:
1080
*Column percentages.
#Row percentages.
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MRI or SPECT will be replaced using a conservative strategy in
favor of SPECT, where missing information for the experimental
functional MRI in all instances is counted such that sensitivity
and specificity are diminished as compared with SPECT.
If missing values occur for all three diagnostics MRI, VQ-
SPECT, and gold standard (e.g., because the patient decided
against the study directly after written informed consent) and
no further follow-up information is available for the patient,
the patient is omitted from the analysis population and no
imputation will be performed.
Secondary analyses will be performed in line with primary
analyses using point estimates and 95% Wilson confidence
intervals for the various proportions of interest. Safety endpoints
will be evaluated descriptively with absolute and relative
frequencies of complications and malfunctions of MRI and
SPECT and will be compared using risk differences and the Chi2-
tests. As sensitivity analyses, the primary analysis will be repeated
in the per-protocol population based on the blinded reader
assessment, comprising all patients without missing co-primary
endpoints. Additionally, a sensitivity analysis will be conducted
in the per-protocol population based on the in-place assessment,
comprising all patients, where in-place MRI diagnosis has been
entered into the eCRF before SPECT assessment so that the
blinding can be considered to be intact.
Methods Against Bias
All centers document the age and gender of all patients with
suspected CTEPH undergoing SPECT in a screening log. There
is agreement that information will be made available in all
centers from the hospital administration to assess the degree of
representativeness of the investigated patient population for the
overall CTEPH-population.
It is the primary aim of this diagnostic study to demonstrate
perfect agreement between SPECT and functional MRI in all
cases, where the SPECT can be considered to be correct.
Therefore, it is of utmost importance that the two diagnostic tests
are conducted and evaluated independently. To ensure internal
validity of the co-primary endpoint, the diagnoses used in the
primary analysis are determined in a standardized blinded reader
assessment of the SPECT and MRI images.
Standard operating procedures are developed for each study
site in order to achieve that the in-place assessment of MRI
and SPECT is performed independently and blinded against
each other.
Before commencement of the CHANGE-MRI study at the
respective centers, local readers are trained on the basis of ∼15
MRI test cases that are provided by the centers to exclude effects
of learning curves on the outcome measures.
DISCUSSION
In this study also Q-SPECT/CT is accepted as an approximation
of the VQ-SPECT as reference test, reflecting current clinical
practice and real-world test performance, although not in
compliance with the current ESC/ERS guidelines (8, 17). This
omission of V-SPECT will affect in particular specificity of
the reference test in cases of Q-SPECT/CT, for CT cannot be
regarded as a fully equivalent substitute for V SPECT.
For primary evaluation, the blinded reader assessment
of SPECT and MRI are used to ensure the independency
of the assessments and maximize internal validity. On
the other hand, external validity of the results might be
reduced by the standardized blinded assessment, which does
not necessarily reproduce the clinical field of application
completely. Consequently, for analyzing the external validity
and generalizability of the results based on the primary blinded
assessment, the in-place assessments of SPECT and MRI are
used as secondary endpoints. While the independence of
these assessments cannot be guaranteed, the clinical setting is
well represented.
To avoid an increased radiation burden, in this trial
the current gold-standard instrument CPA/CTPA is routinely
only applied in SPECT-positive patients, which might induce
differential verification bias (6, 19, 20). To mitigate this
limitation, the follow-up information up to 1 year after study
inclusion will be included into the final diagnosis of PE by
correcting negative cases, which subsequently are identified as
positive in the follow-up period or (although less probable)
correcting positive cases, which subsequently are identified
as negative.
Ethics votes from the Institutional Review Boards at all
participating centers were obtained. The CHANGE-MRI study is
designed so that no extra radiation in addition to the clinically
indicated radiation-based imaging tests is applied to the study
participants. Thus, approval by the Federal Office for radiation
protection (Bundesamt für Strahlenschutz) was not required.
This study is conducted in compliance with the Declaration
of Helsinki, ICH-E6-guidance, and for design issues regarding
diagnostic validation studies, and the EMA Guideline on the
Clinical Evaluation of Diagnostic Agents.
The multicenter CHANGE-MRI study could pave the way for
lungMRImethods to be an equal rights alternative to VQ-SPECT
in the diagnostic pathway for CTEPH. By generating robust
evidence both from in-place assessments and a standardized
blinded reader assessment, this trial will generate the data needed
for a thorough comparison of SPECT and MRI technology.
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